Long-term safety of NTQ5082 for continued treatment
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests the long-term safety and effectiveness of NTQ5082 for people who have already taken part in a previous NTQ5082 study and benefited from it, or who were in the control group and received eculizumab. It aims to see if continued treatment is safe and helpful over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have already completed a previous NTQ5082 study and your doctor thinks you benefited and will continue to benefit, or you were in the control group and got eculizumab.
- You have had the required meningococcal and pneumococcal vaccines as per the earlier study, and the protection from those vaccines will last through this study.
- You agree to use effective birth control during sex from now until 4 weeks after your last dose, and you will not freeze or donate sperm or eggs.
- You agree to sign a consent form to join the study.
- You have not had a bone marrow, stem cell, or solid organ transplant, or had your spleen removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
This study tests a single oral dose of a new medicine (MY008211A) to see how it affects the heart's electrical activity (QT interval) in healthy volunteers. It is a Phase 1 trial to check for safety before moving to larger studies.
This Phase 2 study tests how well and how safely NM8074 works for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not recently received a similar “complement inhibitor” medicine. It may help reduce PNH-related blood cell breakdown and anemia, and it will closely monitor side effects.
This study is for people with paroxysmal nocturnal hemoglobinuria (PNH) who have already taken the experimental drug HSK39297. It checks the long-term safety of continuing the treatment and makes sure it is still helpful.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.